Search Results
May 28, 2026, 07:00 ET PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure
treated in this phase, PMB-CT01 demonstrated a promising safety profile with no dose-limiting toxicities, no grade >1 cytokine release syndrome (CRS), and no grade >1 immune effector cell-associated neurotoxicity syndrome (ICANS). Seven of nine patients (78%) achieved a complete response (CR).
More news about: PeproMene Bio, Inc.
May 28, 2026, 06:14 ET Mews dévoile son système d'exploitation pour l'hôtellerie
ce pari s'avère payant.« L'industrie hôtelière a jusqu'à présent fonctionné sur une grille de catégories conçue il y a quarante ans. PMS, RMS, CRS, CRM, POS : ce ne sont pas des choses réelles. Il s'agit d'acronymes inventés par les éditeurs de logiciels pour vendre plus de logiciels. Dans Mews,
More news about: Mews
May 28, 2026, 06:11 ET Mews stellt das Betriebssystem für das Gastgewerbe vor
sind. Heute zahlt sich diese Annahme aus.„Die Hotelbranche arbeitet mit einem Kategorienmodell, das vor vierzig Jahren entworfen wurde. PMS, RMS, CRS, CRM, POS – das sind keine realen Dinge. Es sind Akronyme, die Softwareunternehmen erfunden haben, um mehr Software zu verkaufen. Innerhalb von Mews
More news about: Mews
May 28, 2026, 06:08 ET Mews presenta el sistema operativo para la hostelería
artificiales. Hoy, esa apuesta ha dado sus frutos."La industria hotelera se ha basado en un modelo de categorías trazado hace cuarenta años. PMS, RMS, CRS, CRM, POS: no son conceptos reales. Son acrónimos inventados por empresas de software para vender más software. En Mews, esas categorías no existen como
More news about: Mews
May 27, 2026, 20:00 ET Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer
for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies,
More news about: Antengene Corporation Limited
May 27, 2026, 11:59 ET Mews Unveils the Operating System for Hospitality
hotel systems were artificial. Today, that bet pays off."The hotel industry has been running on a category map drawn forty years ago. PMS, RMS, CRS, CRM, POS – these aren't real things. They're acronyms invented by software companies to sell more software. Inside Mews, those categories don't exist
More news about: Mews
May 27, 2026, 11:36 ET Mews Unveils the Operating System for Hospitality
hotel systems were artificial. Today, that bet pays off."The hotel industry has been running on a category map drawn forty years ago. PMS, RMS, CRS, CRM, POS – these aren't real things. They're acronyms invented by software companies to sell more software. Inside Mews, those categories don't exist
More news about: Mews
May 26, 2026, 10:30 ET 5W AI Communications Publishes The Retrieval Index -- First Reference Work Mapping How AI Engines Choose Their Sources
pharmaceutical questions — not Pfizer, Merck, or Novartis.The Federal-Document Anchor (Government): The Federal Register, Congress.gov, CRS reports, GAO, and the White House operate as the citation backbone above the political press.MethodologyScores are directional
More news about: 5W Public Relations
May 21, 2026, 18:46 ET AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
duration of response was 13 months. No new safety signals were observed. Despite no step-up dosing (SUD) in this cohort, all cytokine release syndrome (CRS) reported (57%) were grade 1 and 2.5 Additional findings to be presented at the meeting.Further information on AbbVie
More news about: AbbVie
May 21, 2026, 10:00 ET OpenSSF Notes Quarter of Growth with New Members, Added AI Security Resources, and Growing Community
foundation. The OpenSSF also notes additional technical resources for Python secure coding, the first cohort of OpenSSF Ambassadors, and new projects like OSS-CRS joining the foundation's sandbox during
More news about: OpenSSF
May 20, 2026, 06:57 ET METiS TechBio to Present Late-Breaking Data on Near-Complete Cardiomyocyte Delivery at CRS 2026
Late-Breaking oral presentation at the 2026 Controlled Release Society (CRS) Annual Meeting. Dr. Andong Liu, Vice President and Head of Technology Platform at METiS TechBio, will deliver a Late-Breaking oral presentation at the 2026 CRS Annual Meeting in Lisbon, Portugal, this July. The presentation is titled
More news about: METiS TechBio
May 19, 2026, 20:00 ET Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline
for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies,
More news about: Antengene Corporation Limited
May 19, 2026, 09:00 ET Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
disease than the autologous CAR-T platforms that defined the cell therapy story of the prior decade. Clinical data from 2023 through 2026 has shown CRS incidence rates of less than 10% for NK therapies compared to 70%+ for some CAR-T products — a safety profile that has made NK platforms more suitable
More news about: Equity Insider
May 18, 2026, 07:01 ET Kali Therapeutics Announces Oral Presentation of KT502, a Novel CD19 x CD3 T-Cell Engager, at the EULAR 2026 Annual Congress
engagement platform. It is designed to optimize the balance between B-cell killing and T-cell activation, minimizing the risk of Cytokine Release Syndrome (CRS) while enabling the complete removal of pathogenic B-cell populations in autoimmune disease.About Kali TherapeuticsKali Therapeutics
More news about: Kali Therapeutics
May 15, 2026, 08:00 ET Dominari Holdings Congratulates Cerebras Systems on "Blockbuster" Initial Public Offering
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
May 13, 2026, 11:07 ET Antarctic Microbes Put Survival to the Test in Space
materials, and move new stem cell research toward clinical use.For more information about the research launching on this mission, visit the SpaceX CRS-34
More news about: International Space Station National Lab
May 13, 2026, 08:00 ET Dominari Holdings Issues Shareholder Letter
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
May 13, 2026, 07:00 ET Dominari Q1 Revenue Increases by 395% Over Q1 2025
the principal invested. You can check the background of Dominari Securities LLC and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
May 11, 2026, 11:48 ET /C O R R E C T I O N -- Anixa Biosciences, Inc./
route.There have been no observations of Immune Effector Cell-Associated Neurotoxicity Syndrome ("ICANS") or significant Cytokine Release Syndrome ("CRS").All significant adverse events observed to date have been unrelated to lira-cel administration.Dr. Amit Kumar, Chairman and Chief
More news about: Anixa Biosciences, Inc.
May 11, 2026, 07:00 ET Leads Biolabs R&D Symposium: Platform Synergy and Multi-Mechanism Integration Reshape the Immuno-Oncology Landscape
populations through bystander effects and T-cell redirection. This significantly expands the eligible patient population and substantially reduces the risk of CRS, enhancing efficacy while simultaneously improving safety.Through the progressive synergy of its technology platforms and the deep integration
More news about: Nanjing Leads Biolabs Co., Ltd.
May 04, 2026, 10:48 ET Aarti Industries Delivers Resilient Performance in Q4; Strengthens Global Positioning Amid Volatile Macro Environment
EBITDA stood at ₹342 Cr, compared to ₹323 Cr in the previous quarter. The finance cost for the quarter included a revaluation loss of about 39 crs on its long-term foreign-currency loan, due to the steep depreciation of the INR during the quarter.PAT stood at ₹137 Cr, compared to ₹133
More news about: Aarti Industries Limited
May 04, 2026, 08:00 ET Dominari Holdings Announces Record Date for Cash Dividend
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
Apr 30, 2026, 20:57 ET /C O R R E C T I O N -- Realberry/
recommendations regarding any particular security, strategy, or investment. Securities offered through North Capital Private Securities, Member FINRA/SIPC. Its Form CRS may be found
More news about: Realberry
Apr 23, 2026, 09:00 ET Pentagon Counter-Drone Priority Meets Defense AI: Video Intelligence Joins the RF Sensing Stack
Issues for Congress,' updated January 2026. https://www.congress.gov/crs-product/IF12611[3] Breaking Defense, ''It's alive': Biden-era Replicator drone initiative lives on as DAWG, looking at bigger UASs,' December
More news about: USA News Group
Apr 21, 2026, 09:00 ET Cowbell Launches Prime One in the U.S., Introducing Cyber Coverage for Emerging AI and Quantum Risks
a one-year complimentary subscription to Cowbell's Vendor Risk Assessment and Cybersecurity Awareness Training through Cowbell Resiliency Services (CRS). Additionally, policyholders who subscribe to Cowbell's Managed Detection and Response (MDR) service may be eligible for the Prime One MDR Endorsement,
More news about: Cowbell Cyber, Inc. / ICR